CN115779083A - 下调Tp73蛋白表达的物质在制备治疗酒依赖的药物中的应用 - Google Patents
下调Tp73蛋白表达的物质在制备治疗酒依赖的药物中的应用 Download PDFInfo
- Publication number
- CN115779083A CN115779083A CN202210937429.8A CN202210937429A CN115779083A CN 115779083 A CN115779083 A CN 115779083A CN 202210937429 A CN202210937429 A CN 202210937429A CN 115779083 A CN115779083 A CN 115779083A
- Authority
- CN
- China
- Prior art keywords
- group
- alcohol dependence
- expression
- protein
- rats
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000014509 gene expression Effects 0.000 title claims abstract description 32
- 208000007848 Alcoholism Diseases 0.000 title claims abstract description 25
- 201000007930 alcohol dependence Diseases 0.000 title claims abstract description 25
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 23
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 18
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 239000000126 substance Substances 0.000 title claims abstract description 11
- 230000002222 downregulating effect Effects 0.000 title claims abstract description 8
- 208000019901 Anxiety disease Diseases 0.000 claims abstract description 10
- 230000036506 anxiety Effects 0.000 claims abstract description 9
- 101150097193 Tp73 gene Proteins 0.000 claims abstract description 7
- 241000702421 Dependoparvovirus Species 0.000 claims description 11
- 239000013604 expression vector Substances 0.000 claims description 2
- 230000008897 memory decline Effects 0.000 claims description 2
- 102000018252 Tumor Protein p73 Human genes 0.000 abstract description 17
- 108010091356 Tumor Protein p73 Proteins 0.000 abstract description 17
- 230000000971 hippocampal effect Effects 0.000 abstract description 12
- 230000015654 memory Effects 0.000 abstract description 7
- 238000011552 rat model Methods 0.000 abstract description 5
- 230000006399 behavior Effects 0.000 abstract description 4
- 230000019581 neuron apoptotic process Effects 0.000 abstract description 3
- 230000007087 memory ability Effects 0.000 abstract description 2
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000001737 promoting effect Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 45
- 239000013612 plasmid Substances 0.000 description 17
- 239000007924 injection Substances 0.000 description 15
- 238000002347 injection Methods 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- 238000012360 testing method Methods 0.000 description 12
- 230000001419 dependent effect Effects 0.000 description 11
- 108020004459 Small interfering RNA Proteins 0.000 description 10
- 241000700605 Viruses Species 0.000 description 9
- 210000004556 brain Anatomy 0.000 description 9
- 238000002474 experimental method Methods 0.000 description 8
- 230000002018 overexpression Effects 0.000 description 8
- 230000001105 regulatory effect Effects 0.000 description 8
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 108700000707 bcl-2-Associated X Proteins 0.000 description 7
- 102000055102 bcl-2-Associated X Human genes 0.000 description 7
- 210000004027 cell Anatomy 0.000 description 7
- 210000001320 hippocampus Anatomy 0.000 description 6
- 238000012549 training Methods 0.000 description 6
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000011002 quantification Methods 0.000 description 5
- 238000001262 western blot Methods 0.000 description 5
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 4
- 230000009368 gene silencing by RNA Effects 0.000 description 4
- 102100027308 Apoptosis regulator BAX Human genes 0.000 description 3
- 108090000397 Caspase 3 Proteins 0.000 description 3
- 102000003952 Caspase 3 Human genes 0.000 description 3
- 101000911513 Homo sapiens Uncharacterized protein FAM215A Proteins 0.000 description 3
- 108010090931 Proto-Oncogene Proteins c-bcl-2 Proteins 0.000 description 3
- 102000013535 Proto-Oncogene Proteins c-bcl-2 Human genes 0.000 description 3
- 102100026728 Uncharacterized protein FAM215A Human genes 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 239000013607 AAV vector Substances 0.000 description 2
- 101150017888 Bcl2 gene Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- 210000000683 abdominal cavity Anatomy 0.000 description 2
- 125000003158 alcohol group Chemical group 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000003197 gene knockdown Methods 0.000 description 2
- 238000003125 immunofluorescent labeling Methods 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000004393 prognosis Methods 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- YPSXFMHXRZAGTG-UHFFFAOYSA-N 4-methoxy-2-[2-(5-methoxy-2-nitrosophenyl)ethyl]-1-nitrosobenzene Chemical compound COC1=CC=C(N=O)C(CCC=2C(=CC=C(OC)C=2)N=O)=C1 YPSXFMHXRZAGTG-UHFFFAOYSA-N 0.000 description 1
- 101150105054 CCKBR gene Proteins 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010013654 Drug abuse Diseases 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 1
- 208000028389 Nerve injury Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 108010016828 adenylyl sulfate-ammonia adenylyltransferase Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000012550 audit Methods 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 239000000090 biomarker Substances 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000003759 clinical diagnosis Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 238000001917 fluorescence detection Methods 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 238000001215 fluorescent labelling Methods 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 230000006386 memory function Effects 0.000 description 1
- 230000008764 nerve damage Effects 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 230000002360 prefrontal effect Effects 0.000 description 1
- 238000002331 protein detection Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000006886 spatial memory Effects 0.000 description 1
- 230000007596 spatial working memory Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 208000011117 substance-related disease Diseases 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
Images
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
Description
Claims (6)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210937429.8A CN115779083B (zh) | 2022-08-05 | 2022-08-05 | 下调Tp73蛋白表达的物质在制备治疗酒依赖的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202210937429.8A CN115779083B (zh) | 2022-08-05 | 2022-08-05 | 下调Tp73蛋白表达的物质在制备治疗酒依赖的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN115779083A true CN115779083A (zh) | 2023-03-14 |
CN115779083B CN115779083B (zh) | 2024-04-02 |
Family
ID=85431463
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210937429.8A Active CN115779083B (zh) | 2022-08-05 | 2022-08-05 | 下调Tp73蛋白表达的物质在制备治疗酒依赖的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN115779083B (zh) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170360961A1 (en) * | 2014-12-30 | 2017-12-21 | Universidad De Chile | Aav/xbp1s-ha virus, gene therapy method and use thereof in the optimisation and improvement of learning, memory and cognitive capacities |
CN108324704A (zh) * | 2018-01-25 | 2018-07-27 | 新乡医学院 | 用于减轻慢性酒精中毒引起机体损伤的药物 |
-
2022
- 2022-08-05 CN CN202210937429.8A patent/CN115779083B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20170360961A1 (en) * | 2014-12-30 | 2017-12-21 | Universidad De Chile | Aav/xbp1s-ha virus, gene therapy method and use thereof in the optimisation and improvement of learning, memory and cognitive capacities |
CN108324704A (zh) * | 2018-01-25 | 2018-07-27 | 新乡医学院 | 用于减轻慢性酒精中毒引起机体损伤的药物 |
Non-Patent Citations (2)
Title |
---|
杨彬: "酒依赖大鼠海马脑区的miRNA和mRNA表达分析及miR-96-5p靶基因与功能验证", 《中国优秀硕士学位论文全文数据库 医药卫生科技辑》, no. 12, pages 071 - 66 * |
黄玲玲等: "大鼠Tp73基因重组腺病毒载体构建及鉴定", 《黑龙江医药科学》, vol. 37, no. 1, 28 February 2014 (2014-02-28), pages 81 - 83 * |
Also Published As
Publication number | Publication date |
---|---|
CN115779083B (zh) | 2024-04-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Xu et al. | Clinical presentation and outcome of pediatric patients with hemophagocytic lymphohistiocytosis in China: a retrospective multicenter study | |
Lodato et al. | Loss of COUP-TFI alters the balance between caudal ganglionic eminence-and medial ganglionic eminence-derived cortical interneurons and results in resistance to epilepsy | |
Stamm et al. | An alternative-exon database and its statistical analysis | |
US7250496B2 (en) | Bioinformatically detectable group of novel regulatory genes and uses thereof | |
Rossner et al. | Global transcriptome analysis of genetically identified neurons in the adult cortex | |
Cebrián-Silla et al. | Unique organization of the nuclear envelope in the post-natal quiescent neural stem cells | |
Lee et al. | Signature morphoelectric properties of diverse GABAergic interneurons in the human neocortex | |
Brooks et al. | Ferritin crystal cataracts in hereditary hyperferritinemia cataract syndrome | |
Raju et al. | Secretagogin is expressed by developing neocortical GABAergic neurons in humans but not mice and increases neurite arbor size and complexity | |
EP3081646A1 (en) | Non-coding rna of salmonella and identification and use thereof | |
Muheim et al. | Dynamic-and frequency-specific regulation of sleep oscillations by cortical potassium channels | |
Pérez-Hernández et al. | Transcriptomic coupling of PKP2 with inflammatory and immune pathways endogenous to adult cardiac myocytes | |
Chen et al. | Challenges and opportunities for precision medicine in neurodevelopmental disorders | |
Lawler et al. | Machine learning sequence prioritization for cell type-specific enhancer design | |
Sellnow et al. | Striatal Nurr1 facilitates the dyskinetic state and exacerbates levodopa-induced dyskinesia in a rat model of Parkinson's disease | |
Krienen et al. | A marmoset brain cell census reveals regional specialization of cellular identities | |
Liu et al. | Mesangial cell: A hub in lupus nephritis | |
CN106030302A (zh) | 治疗神经变性疾病 | |
CN115779083A (zh) | 下调Tp73蛋白表达的物质在制备治疗酒依赖的药物中的应用 | |
US20210170051A1 (en) | Feedback enabled synthetic genes, target seed match cassettes, and their uses | |
Yu et al. | Regulation of embryonic and adult neurogenesis by Ars2 | |
CN115851947A (zh) | Dagla在肝癌诊治中的应用 | |
AU2022371414A1 (en) | Isolated glial progenitor cells for use in the competition treatment of age-related white matter loss | |
CN114470209A (zh) | Trim2在防治猪流行性腹泻病毒感染中的应用 | |
Wang et al. | Somatosensory neurons express specific sets of lincRNAs, and lincRNA CLAP promotes itch sensation in mice |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Qi Inventor after: Yu Shuai Inventor after: Zhang Xiaoyang Inventor after: Li Duan Inventor after: Zhang Ruiling Inventor after: Li Lin Inventor after: Zhang Yanjie Inventor after: Hou Yunsheng Inventor after: Cheng Guiding Inventor after: Li Wenhui Inventor after: Ning Kui Inventor before: Wang Qi Inventor before: Yu Shuai Inventor before: Zhang Xiaoyang Inventor before: Li Rui Inventor before: Zhang Ruiling Inventor before: Li Lin Inventor before: Zhang Yanjie Inventor before: Hou Yunsheng Inventor before: Cheng Guiding Inventor before: Li Wenhui Inventor before: Ning Kui |
|
CB03 | Change of inventor or designer information | ||
GR01 | Patent grant | ||
GR01 | Patent grant |